KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.

Murdo Ferguson, Tino F Schwarz, Sebastián A Núñez, Juan Rodríguez-García, Marek Mital, Carlos Zala, Bonavuth Pek, Bernhard Schmitt, Nicole Toursarkissian, Dolores Ochoa Mazarro, Josef Großkopf, Christine Voors-Pette, Hemalini Mehta, Hiwot Amare Hailemariam, Catherine Gérard, Silvia Damaso, Marie-Pierre David, Dominique Descamps, Judith Hill, Corinne Vandermeulen, Veronica Hulstrøm

Hum Vaccin Immunother 21(1) 2579335

PMID41194599
PMCIDPMC12599337
DOI10.1080/21645515.2025.2579335
发表日期2025-11-06
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:研究设计图;Figure 3:AI 判定为 flow diagram;Figure 4:AI 判定为 other。
摘要

摘要

In this phase 3, randomized, placebo-controlled multi-country study, the AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine (adjuvanted RSVPreF3) was immunologically non-inferior at 1 month post-vaccination in adults 50-59 years of age (YOA) compared to adults ≥60 YOA, in whom efficacy was previously demonstrated. Here, we report end-of-study immunogenicity and safety results until 12 months post-vaccination. Participants 50-59 YOA were divided into an at-increased-risk (AIR) and a non-AIR subcohort, each randomized (2:1) to receive one dose of adjuvanted RSVPreF3 or placebo. A control cohort of participants ≥60 YOA received adjuvanted RSVPreF3. Humoral/cell-mediated immunity and safety were assessed. In total, 1152 participants 50-59 YOA received adjuvanted RSVPreF3 or placebo, and 381 participants ≥60 YOA received adjuvanted RSVPreF3. In all vaccinated groups, RSV-A and RSV-B neutralizing titers and RSVPreF3-specific polyfunctional CD4+ T-cell frequencies increased at 1 month post-vaccination and declined thereafter, but remained above baseline and placebo levels at 6 and 12 months post-vaccination. During the study, one vaccine-related serious adverse event (cold-type hemolytic anemia in a participant ≥60 YOA) was reported. Five participants died (all in the 50-59 YOA AIR subcohort, four had received adjuvanted RSVPreF3, one placebo); none of the deaths were considered vaccine-related. In conclusion, adjuvanted RSVPreF3 induced a humoral and cell-mediated immune response persisting until at least 12 months post-vaccination in adults 50-59 YOA, including those at increased risk for RSV disease. The vaccine had an acceptable 12-month safety profile in adults 50-59 YOA, consistent with that in adults ≥60 YOA.Trial Registration: ClinicalTrials.gov: NCT05590403.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Plain language summary.
非 KM Figure
Figure 2Figure 2. Study design. Adapted from Ferguson et al.
非 KM Figure
Figure 3Figure 3. Flow of participants.
非 KM Figure
Figure 4Figure 4. RSV-A (a) and RSV-B (b) geometric mean neutralizing titers and mean geometric increases (per-protocol set for humoral immunogenicity).
非 KM Figure